The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment

Hou, Yi-ChouYi-ChouHouChueh, Ti-ITi-IChuehLu, Kuo-ChengKuo-ChengLuLiu, Yi-ChienYi-ChienLiuChen, Tso-HsiaoTso-HsiaoChenSHING-HWA LIUChen, Ruei-MingRuei-MingChen2024-03-272024-03-2720241387287718758908https://scholars.lib.ntu.edu.tw/handle/123456789/641431Cognitive impairment (CI) is one of the major complications in chronic kidney disease patients, especially those with end-stage renal disease (ESRD). Limited biomarkers have been found that can significantly predict ESRD-associated cognitive decline.enAlbumin; Alzheimer’s disease; amyloid-beta 1-42; biomarker signature; cognitive impairment; end-stage renal diseaseThe Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairmentjournal article10.3233/JAD-230747382507712-s2.0-85184001115https://api.elsevier.com/content/abstract/scopus_id/85184001115https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184001115&doi=10.3233%2fJAD-230747&partnerID=40&md5=da7554aeaf2fd0033fbb5c203d21b548